Delving into the Latest Updates on Clover Biopharmaceuticals Aus Pty Ltd. with Synapse

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Reactogenicity and Immunogenicity of a Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T) in Children 2 to <6 Years of Age

This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T) in children 2-<6 years of age.

开始日期2025-03-15

申办/合作机构

Clover Biopharmaceuticals Aus Pty Ltd.

NCT06194318 / Recruiting临床1期

A Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1019 in Healthy Adults

This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the bivalent SCB-1019 vaccine candidate with or without aluminium hydroxide in young adults (18-59 years) and older adults (60-85 years).

开始日期2023-12-13

申办/合作机构

Clover Biopharmaceuticals Aus Pty Ltd.

NCT06567457 / Withdrawn临床3期

Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Monovalent Omicron XBB.1.5 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 Vaccine

The purpose of this study is to assess the immunogenicity and safety of SCB-2023B monovalent Omicron XBB.1.5 vaccine compared to the prototype SCB-2019 vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19 vaccine ≥6 months prior to enrollment.

开始日期2023-10-01

申办/合作机构

Clover Biopharmaceuticals Aus Pty Ltd.

100 项与 Clover Biopharmaceuticals Aus Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Clover Biopharmaceuticals Aus Pty Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Clover Biopharmaceuticals Aus Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Clover Biopharmaceuticals Aus Pty Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月17日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

1

临床3期

其他

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

COVID-19 S-Trimer vaccine (Sichuan Clover Biopharmaceuticals, Inc) ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	临床3期
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)(Clover Biopharmaceuticals)	呼吸道合胞体病毒感染更多	临床1期
COVID-19 trimeric S-protein subunit vaccine(trivalent)(Clover Biopharmaceuticals AUS) ( SARS-CoV S protein )	新型冠状病毒感染更多	终止
阿柏西普生物类似药(四川三叶草生物制药有限公司) ( PGF x VEGF-A )	湿性年龄相关性黄斑变性更多	终止
SCB-2020S ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	终止